In subsequent studies: PIONEER-6 and ELIXA the primary endpoints (death from cardiovascular causes, nonfatal myocardial infarction, or nonfatal stroke, hospitalization for unstable angina) were not met in the GLP-1 RAs group, but a significant decrease in glycated hemoglobin was observed. This evidence concerns the gene GLP1R and stroke disorder.